- Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio across herpesviruses and hepatitis B and D viruses
- Initial clinical data anticipated by end of year from first-in-human study of long-acting helicase-primase inhibitor targeting recurrent genital herpes (ABI-5366) and Phase 1b study of next-generation core inhibitor for chronic hepatitis B virus (ABI-4334)
- Recently announced long-term partnership with Gilead Sciences, Inc. (Gilead) to address serious viral diseases expands and builds on the progress of Assembly Bio's antiviral portfolio
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today provided an outline of the anticipated milestones and progress for its clinical pipeline during 2024.
"We are thrilled with the rapid progress of multiple programs from our expanded antiviral pipeline, and plan to initiate clinical studies for four development candidates in 2024," said Jason Okazaki, chief executive officer and president of Assembly Bio. "These promising antiviral candidates demonstrate the breadth of our pipeline across herpesviruses, HDV and HBV, and represent an important step towards our goal of significantly improving therapeutic options for patients living with serious viral infections. With the strength of our R&D expertise and the long-term collaboration with Gilead in place, we have the opportunity to build on this momentum in 2024."
Summary of Anticipated Events and Milestones
By mid-year 2024:
- ABI-5366, a long-acting herpes simplex ...